Gapping up
In reaction to strong earnings/guidance:
- RAD +8.9%, DRI +3.1%, FUL +2.6%, FDS +2.6%, MKC +1.6%, ACN +1.6%
M&A news:
- ALLY +7.5% (Ally and CardWorks agree to terminate merger)
Other news:
- BDN +5.6% (to join S&P SmallCap 600)
- RPAI +5.5% (to join S&P SmallCap 600)
- XLRN +3.4% (clinical data released)
- MYGN +2.6% (reports that a new study published in Future Medicine demonstrates the ability of myPath Melanoma to accurately classify skin lesions ruled indeterminate by standard pathological review)
- MRNA +2.4% (Moderna and Catalent (CTLT) announced a collaboration for large-scale, commercial fill-finish manufacturing of Moderna's mRNA-based COVID-19 vaccine candidate (mRNA-1273) at Catalent's biologics facility)
- INSM +1.7% (positive results from Phase 2 WILLOW study)
Analyst comments:
- PDCO +2.1% (upgraded to Neutral from Sell at Goldman)
- AHH +0.8% (upgraded to Hold from Sell at Stifel)
- AVAV +0.7% (upgraded to Buy from Hold at Stifel)